• support@madhedgefundtrader.com
  • Member Login
Mad Hedge Fund Trader
  • Home
  • About
  • Store
  • Luncheons
  • Testimonials
  • Contact Us
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu

Rotating Into Health Care

Diary, Newsletter

There has been no more despised sector in the stock market for the past eight months than health care and biotech.

Ever since presidential aspirant Hillary Clinton launched the Tweet that sank the troubled sector in August, both political parties have taken turns beating it up, like tag team wrestlers.

Clinton wants more competition in the industry and an end to price gouging, naming companies by name, like Valeant Pharmaceuticals (VRX) as guilty parties. Trump is demanding more competition from foreign imports.

Ted Cruz intends to demolish that great wellspring of health care profits, Obamacare, on his first day in office. Bernie Sander wants to nationalize the lot.

Traders and investors can be forgiven for not wanting to touch health care with a ten-foot pole. The stocks responded by cratering a heart rending 30%-80%.

However, a funny thing has happened over the last few weeks. Health care and biotech stocks have started going up.

And you know what? They are going to keep going up. In fact, I think that health care, along with banks, and energy will be your big alpha plays for 2016.

The sector has one big thing going for it: the calendar.

Each passing day brings the end of the current election closer, and the end of the present onslaught on the sector. Think of all the negativity as an option approaching accelerated time decay.

And here?s the crucial thing about health care. The earnings story never went away, only the share valuations did. Health care and biotech remain the healthiest segments of US industry with the greatest earnings prospects.

China, eat your heart out!

So fall down on your knees and thanks the politicians for a gift that will keep on giving. Their fulminating is enabling you to get into one of the best industries at the cheapest possible prices.

The shopping list is rich.

AbbVie (ABBV) was spun off from Abbot Labs in 2013. It has a relatively low cost cancer drug, Imbruvica, that dodges political risk. It also sells a blockbuster rheumatoid arthritis drug, Humira, and a hot thyroid drug. Earning per share will double in two years.

Boston Scientific (BSX) has a solid market share in medical devices, one of the safest corners of the health care field. No controversial $100,000 cures here. So does Thermofisher (TMO).

Gilead Sciences (GLD) is a name my Trade Alert followers already know and love, having made fortunes there in the last couple of years. They have the last word in a hepatitis cure, Solvaldi. For more depth on the compan,y please read my latest opus by clicking here for ?Keep Gilead Sciences on Your Radar?? (note: you have to be logged in to read it).

Celgene (CELG) has several blockbuster drugs in the pipeline treating psoriasis (Otezla), blood cancer (Revlimid), and cancer (Abraxane). A classic baby boomer retirement play, the company should double in value in five years.

Finally, if you want to take a safer basket play, look at the IShares NASDAQ Biotechnology Index ETF (IBB). Their top holdings include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Biogen (BIIB), and Regeneron Pharmaceuticals (REGN).

To view its prospectus, please click here.

As for Valeant Pharmaceuticals (VRX), I wouldn?t touch IT with a ten-foot pole.

ABBV
GILD
CELG
BSX
Imbruvica

Share this entry
  • Share on Facebook
  • Share on X
  • Share on WhatsApp
  • Share on Pinterest
  • Share on LinkedIn
  • Share by Mail
https://www.madhedgefundtrader.com/wp-content/uploads/2016/04/Imbruvica-e1460595213654.jpg 271 400 DougD https://madhedgefundtrader.com/wp-content/uploads/2019/05/cropped-mad-hedge-logo-transparent-192x192_f9578834168ba24df3eb53916a12c882.png DougD2016-04-14 01:08:322016-04-14 01:08:32Rotating Into Health Care

tastytrade, Inc. (“tastytrade”) has entered into a Marketing Agreement with Mad Hedge Fund Trader (“Marketing Agent”) whereby tastytrade pays compensation to Marketing Agent to recommend tastytrade’s brokerage services. The existence of this Marketing Agreement should not be deemed as an endorsement or recommendation of Marketing Agent by tastytrade and/or any of its affiliated companies. Neither tastytrade nor any of its affiliated companies is responsible for the privacy practices of Marketing Agent or this website. tastytrade does not warrant the accuracy or content of the products or services offered by Marketing Agent or this website. Marketing Agent is independent and is not an affiliate of tastytrade. 

Legal Disclaimer

There is a very high degree of risk involved in trading. Past results are not indicative of future returns. MadHedgeFundTrader.com and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The indicators, strategies, columns, articles and all other features are for educational purposes only and should not be construed as investment advice. Information for futures trading observations are obtained from sources believed to be reliable, but we do not warrant its completeness or accuracy, or warrant any results from the use of the information. Your use of the trading observations is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. You must assess the risk of any trade with your broker and make your own independent decisions regarding any securities mentioned herein. Affiliates of MadHedgeFundTrader.com may have a position or effect transactions in the securities described herein (or options thereon) and/or otherwise employ trading strategies that may be consistent or inconsistent with the provided strategies.

Copyright © 2025. Mad Hedge Fund Trader. All Rights Reserved. support@madhedgefundtrader.com
  • Privacy Policy
  • Disclaimer
  • FAQ
Link to: How to Avoid Ponzi Schemes Link to: How to Avoid Ponzi Schemes How to Avoid Ponzi Schemes Link to: April 18 Miami Global Strategy Luncheon Link to: April 18 Miami Global Strategy Luncheon April 18 Miami Global Strategy Luncheon
Scroll to top